American Oriental Bioengineering, Inc. issued an update on recent financial and operating events at the company.
American Oriental Bioengineering, Inc. said that the company’s Board of Directors has approved the share buyback program announced recently by the company. The company now has the authority to repurchase up to $20 million of common stock over the next two years.
American Oriental Bioengineering, Inc. has 78.6 million shares outstanding and estimates that the buyback would cover approximately 11.8 million shares using the current stock price.
American Oriental Bioengineering, Inc. recently issued financial results for the 2010 fiscal year, and reported sales of $305.9 million in 2010, up 3% from the $296.2 million reported in 2009. The company attributed the increase to higher demand from its customers and greater sales coverage.
Although American Oriental Bioengineering, Inc. reported higher sales, this did not translate into higher net income for the year. The company reported net income attributable to controlling interest at $16.3 million, or $0.22 per diluted share, in fiscal 2010, compared to $41.4 million, or $0.53 per diluted share, in fiscal 2009.
American Oriental Bioengineering, Inc. is involved in the design and manufacturing of over the counter and prescription medicine.
For more information on the company, go to www.bioaobo.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment